Rockefeller Capital Management’s ADMA Biologics ADMA Stock Holding History

Rockefeller Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.3K	Buy	5,408 +1,983	+58%	+$18.1K	﹤0.01%	3419
2026 Q1	$30.9K	Sell	3,425 -1,060	-24%	-$16.7K	﹤0.01%	3504
2025 Q4	$81.8K	Buy	4,485 +1,694	+61%	+$28.6K	﹤0.01%	2815
2025 Q3	$40.9K	Buy	+2,791	New	+$47.8K	﹤0.01%	3008
2023 Q1	–	Sell	-1,399	Closed	-$5K	–	1992
2022 Q4	$5K	Hold	1,399	–	–	﹤0.01%	3304
2022 Q3	$3K	Hold	1,399	–	–	﹤0.01%	3454
2022 Q2	$2K	Hold	1,399	–	–	﹤0.01%	3739
2022 Q1	$2K	Hold	1,399	–	–	﹤0.01%	3572
2021 Q4	$1K	Sell	1,399 -490	-26%	-$644	﹤0.01%	3613
2021 Q3	$2K	Hold	1,889	–	–	﹤0.01%	3400
2021 Q2	$3K	Hold	1,889	–	–	﹤0.01%	3135
2021 Q1	$3K	Buy	+1,889	New	+$4.32K	﹤0.01%	3000

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rockefeller Capital Management's ADMA Position: Q2 2026 in Review

Rockefeller Capital Management increased its ADMA Biologics (ADMA) stake by 58% in Q2 2026, buying an estimated $18.1K and bringing the position to 5,408 shares worth $45.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

Rockefeller Capital Management first reported a position in ADMA in Q1 2021 and has held it in 12 quarters since. The position peaked at $81.8K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Rockefeller Capital Management held 5,408 shares of ADMA Biologics worth $45.3K as of Q2 2026.
Rockefeller Capital Management bought 1,983 ADMA Biologics shares in Q2 2026, an estimated $18.1K.
ADMA Biologics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3419 holding.
Rockefeller Capital Management first reported a position in ADMA Biologics in Q1 2021 and has held it in 12 quarters since.
Rockefeller Capital Management's ADMA Biologics position peaked at $81.8K in Q4 2025.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.